KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addus HomeCare (ADUS) Gains from Sales and Divestitures (2010 - 2025)

Addus HomeCare posted quarterly Gains from Sales and Divestitures of $123000.0 for Q4 2025, up 19.42% year-on-year from $103000.0 in Q4 2024, and up 19.42% on a QoQ basis from $103000.0 in Q4 2024.

Addus HomeCare (ADUS) has 16 years of Gains from Sales and Divestitures data on file, last reported at $123000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 19.42% year-over-year to $123000.0; the trailing twelve-month figure through Dec 2025 stood at $123000.0 (up 19.42% YoY), and the FY2025 full-year result was $123000.0, up 19.42% from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 stood at $123000.0, up from $103000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $123000.0 in Q4 2025 and bottomed at $74000.0 in Q4 2022.
  • The 5-year median for Gains from Sales and Divestitures is $95000.0 (2023), against an average of $94200.0.
  • The widest annual swing landed in 2022, when Gains from Sales and Divestitures declined 2.63%; it then rose 28.38% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $76000.0 in 2021, then retreated by 2.63% to $74000.0 in 2022, then grew by 28.38% to $95000.0 in 2023, then increased by 8.42% to $103000.0 in 2024, then advanced by 19.42% to $123000.0 in 2025.
  • The last three Gains from Sales and Divestitures figures came in at $123000.0 (Q4 2025), $103000.0 (Q4 2024), and $95000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn
10 Addus HomeCare 1.67 Bn 1.56 Bn 115.87 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 123,000.00
Dec 31, 2025 123,000.00
Dec 31, 2024 103,000.00
Dec 31, 2024 103,000.00
Dec 31, 2023 95,000.00
Dec 31, 2023 95,000.00
Dec 31, 2022 74,000.00
Dec 31, 2022 74,000.00
Dec 31, 2021 76,000.00
Dec 31, 2021 76,000.00
Dec 31, 2020 77,000.00
Dec 31, 2020 77,000.00
Dec 31, 2019 66,000.00
Dec 31, 2019 66,000.00
Dec 31, 2018 55,000.00
Dec 31, 2018 55,000.00
Dec 31, 2017 35,000.00
Dec 31, 2017 35,000.00
Dec 31, 2016 20,000.00
Dec 31, 2016 20,000.00
Dec 31, 2015 38,000.00
Dec 31, 2015 38,000.00
Dec 31, 2014 22,000.00
Dec 31, 2014 22,000.00
Dec 31, 2013 32,000.00
Dec 31, 2013 32,000.00
Dec 31, 2012 20,000.00
Dec 31, 2012 20,000.00
Dec 31, 2011 8,000.00
Dec 31, 2011 8,000.00
Dec 31, 2010 1,000.00
Dec 31, 2010 1,000.00